J Gastroenterol Hepatol
September 2025
Background And Aim: There is no "gold standard" treatment for gastric adenomas due to uncertainty about their malignant potential. We wanted to understand better the factors contributing to their transformation into malignant tumors by analyzing their long-term development, including endoscopic observations and genetic abnormalities.
Methods: A total of 34 gastric tumor specimens from 17 patients were analyzed.
Background/aims: The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.
View Article and Find Full Text PDF